Moderna Q3 EPS $0.38; Raises Full-Year Revenue Growth Outlook
Moderna's stock rose 0.41% in after-hours trading following its Q3 earnings release. The company reported EPS of $0.38, beating expectations, and raised its full-year revenue growth forecast to 15%–25
VolFlash analysis
🔒 Direction
Magnitude ●●○○○
Horizon Days
VolFlash engine · 11921ms
Moderna Q3 EPS beats, raises full-year revenue and cash guidance
- Q3 EPS of $0.38 exceeded consensus estimates
| Asset | Bias | Rationale |
|---|---|---|
| ModernaSTOCKMRNA | 🔒 Members only | 🔒 Members only |
🔒 2 more key points, asset bias and rationale are members-only · Unlock full analysis
Watchlist
- NASDAQ Biotechnology Index (NBI)
- S&P 500 Health Care Sector
- US 10-year Treasury yield
What could invalidate this view
The invalidation conditions are members-only — knowing what would prove this wrong matters as much as the call itself. Unlock full analysis
Public information plus VolFlash reasoning. Not investment advice; no price targets.
Related guidesHow markets transmit
One email a day — don't miss the big ones
The 8 highest-severity events of the past 24h, with our read and source links. Unsubscribe anytime.
Published：2026-11-09 21:19:01 · Source：wallstcn · Automatically aggregated and analysed — verify against the original source.